Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors
BioLineRx Ltd. - American Depositary Shares (BLRX)
Last biolinerx ltd. - american depositary shares earnings: 5/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.biolinerx.com
Company Research
Source: Business Wire
Patent protects the use of GLIX1 in cancers where cytidine deaminase (CDA) is not over-expressed — representing more than 90% of all cancer types OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a biotechnology company pioneering first-in-class TET2-activating therapeutics for difficult-to-treat cancers, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled “Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies” (U.S. Patent Application No. 18/602,969).The patent covers the use of Hemispherian’s lead clinical candidate, GLIX1, for the treatment of cancers in which cytidine deaminase (CDA) is not over-expressed beyond a defined threshold — a characteristic found in over 90% of cancers.This allowance substantially strengthens GLIX1’s intellectual property protection until 2040 with eligibility for up to five additional years. Corresponding applications are pending internationally.“Receiving this
Show less
Read more
Impact Snapshot
Event Time:
BLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLRX alerts
High impacting BioLineRx Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLRX
News
- BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]Yahoo! Finance
- BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR Newswire
- BioLineRx Q3 2025 Earnings Preview [Seeking Alpha]Seeking Alpha
- Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors [Yahoo! Finance]Yahoo! Finance
- BioLineRx to Report Third Quarter 2025 Results on November 24, 2025PR Newswire
BLRX
Sec Filings
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- 9/29/25 - Form 6-K
- BLRX's page on the SEC website